We found that the HDAC4/HDAC5 inhibitor LMK235 at 0.5 μM significantly reduced the cell viability and colony formation of patient-derived, temozolomide-resistant GBM P#5 TMZ-R, U-87 MG, and T98G cells. Here, HDAC5 is linked to glioblastoma.